Purpose Of Review: Cholangiocarcinoma is the second most common primary liver tumour, worldwide. Its incidence and mortality are rising, the cause of which is unclear. Cholangiocarcinoma usually presents late, with obstructive jaundice, malaise, weight loss and discomfort. For most patients, complete surgical resection, the only potential cure, is not possible. Survival length and palliation of symptoms become paramount and often this centres on restoration of bile flow to relieve jaundice and improve general well being. There are now multiple options to achieve this goal and emerging evidence supports certain methods over others.
Recent Findings: For advanced cholangiocarcinoma, endoscopic biliary stenting has become an established treatment. Recent evidence supports the use of metal stents over plastic to improve survival and stent patency. Locoregional therapies, such as radiofrequency ablation, transarterial chemoembolisation and radiotherapy have shown promise in preliminary studies. Landmark studies have established the use of cisplatin and gemcitabine as first-line chemotherapy in advanced cholangiocarcinoma.
Summary: The rise in incidence of advanced cholangiocarcinoma, has necessitated the development of novel therapies to optimize palliation. This article discusses the current options for palliation of cholangiocarcinoma, including stenting, locoregional therapy, surgery, endoscopic ultrasound and palliative chemotherapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/SPC.0b013e32835f1e2f | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advancements in cholangiocarcinoma: evolving strategies for diagnosis, treatment, and palliation over three decades.
Chin Clin Oncol
October 2024
Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Article Synopsis
- - Significant progress has been made in diagnosing and treating cholangiocarcinoma (CC), a serious liver cancer making up 15% of primary liver tumors, though it still accounts for 2% of cancer-related deaths due to its complexity and challenges.
- - Key risk factors include chronic inflammation, genetics, and congenital issues, with CC categorized into intrahepatic and extrahepatic types, both of which have been increasing in incidence over the past two decades.
- - Advancements in imaging, molecular profiling, and the evolution of endoscopic techniques have improved early detection and treatment, while multidisciplinary teams enhance patient care through combined surgical, medical, and palliative approaches.
National guidelines for the diagnosis and treatment of hilar cholangiocarcinoma.
World J Gastroenterol
March 2024
Department of Gastroenterology & Hepatology, Pakistan Kidney and Liver Institute & Research Centre, Lahore 54000, Pakistan.
Article Synopsis
- A consensus meeting of national hepatobiliary experts took place on May 26, 2023, at PKLI & RC, aiming to develop guidelines for managing hilar cholangiocarcinoma (hCCA).
- The meeting emphasized the need for a multidisciplinary approach to manage hCCA effectively, highlighting diagnostic methods like CT and MRI for staging, as well as the importance of surgical resection for potentially curative treatment.
- For patients with unresectable hCCA, options include liver transplantation and palliative chemotherapy, with guidelines suggesting personalized treatment plans based on local discussions.
Multimodal treatment with endoscopic ablation and systemic therapy for cholangiocarcinoma.
Best Pract Res Clin Gastroenterol
February 2024
Asian Institute of Gastroenterology, Hyderabad, India. Electronic address:
Cholangiocarcinoma (CCA) are primary malignancies of biliary system and usually unresectable at the time of diagnosis. As a consequence, majority of these cases are candidates for palliative care. With the advances in chemotherapeutic agents and multidisciplinary care, the survival rate has improved in cases with inoperable malignant biliary obstruction.
View Article and Find Full Text PDFLiver transplantation as an alternative for the treatment of perihilar cholangiocarcinoma: A critical review.
Hepatobiliary Pancreat Dis Int
April 2024
Department of Gastroenterology, Transplantation Unit, Universidade de São Paulo, São Paulo, Brazil.
Background: Perihilar cholangiocarcinoma (phCCC) is a dismal malignancy. There is no consensus regarding the best treatment for patients with unresectable phCCC. The present review aimed to gather the current pieces of evidence for liver transplantation and liver resection as a treatment for phCCC and to build better guidance for clinical practice.
View Article and Find Full Text PDFNew trends in diagnosis and management of gallbladder carcinoma.
World J Gastrointest Oncol
January 2024
2 Propedeutic Department of Surgery, Hippokration General Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki 54642, Greece.
Gallbladder (GB) carcinoma, although relatively rare, is the most common biliary tree cholangiocarcinoma with aggressiveness and poor prognosis. It is closely associated with cholelithiasis and long-standing large (> 3 cm) gallstones in up to 90% of cases. The other main predisposing factors for GB carcinoma include molecular factors such as mutated genes, GB wall calcification (porcelain) or mainly mucosal microcalcifications, and GB polyps ≥ 1 cm in size.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!